|
Extensive scientific and clinical research, anti-Flu and anti-SARS success
Flu-X has undergone more than three years of extensive scientific research & development and animal and human patient clinical trials at China’s leading pharmaceutical and biological products research institutes and regulatory organizations, including China’s Centres for Disease Control (CDC).
Flu-X was developed by Professor D. S. Liu, Ph. D, (for biography click here) one of China's most eminent and respectable virologists and medical doctors, originally as an anti-SARS virus drug during China's SARS epidemic in 2003. Due to its strong anti-viral properties the product was successfully used to treat SARS-infected patients and prevent SARS infection at several hospitals in China.
After the SARS epidemic, further numerous viral inactivation and viral screening experiments* on various viruses and pathogenic bacterial strains were conducted on the Flu-X compound, under World Health Organization (WHO) protocols, and the result of these experiments clearly confirm the Flu-X compound to be highly effective against:
- Influenza Type A and B viruses
- Herpes Simplex 1 and 2 (HSV 1 & 2) viruses
- Human Papilloma virus (HPV)
- H.influenza bacteria
- Aureus staphylococcus bacteria
- A-hemolytic streptococcus bacteria
The chicken embryo viral inactivation experiment results demonstrate and confirm Flu-X to be potent and highly effective in inactivating Influenza A and B viruses with an EID (Egg Infectious Dose) of 107.0 EID50/ml and 106.0 EID50/ml for Influenza Type A and Influenza Type B viruses, respectively.
These scientific studies, together with the numerous animal and human patient clinical trials and pharmaceutical toxicology studies (see Clinical Trials) confirm Flu-X’s ability to safely and effectively inactivate and kill the Influenza A and B viruses and, further, prevent replication of these viruses, while being very safe for human use.
*The above experiments were conducted at the:
|
